Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

In 173 patients from MITO16a/MaNGO-OV2a (393 plasma samples), post-surgical tumor fraction was detectable in 97% and, with fragmentomic profiles, was associated with PFS and OS independently of clinical covariates.

ESMO OpenPubMed 41747586DOI 10.1016/j.esmoop.2026.106087